Latest Takeovers Panel News

Antony Sage, founding director of Cyclone Metals, has lodged an application with the Takeovers Panel alleging coordinated shareholder actions to alter the board without proper disclosure. The dispute intensifies as Cyclone schedules a new meeting to consider further director removals.

ASPI Isotopes Inc. and Renergen Limited have received regulatory clearance to proceed with their Scheme of Arrangement, setting a detailed timetable for share suspensions, listings, and settlements complicated by cross-border processes.

Renergen Limited and ASP Isotopes Inc. have cleared all conditions for their merger scheme, setting the stage for integration and a production update from the Virginia Gas Project early next year.

The Takeovers Panel has declined to find unacceptable circumstances in Emu NL’s recent placement before its AGM, ruling no control effect was evident. This decision underscores regulatory caution around capital raises near board votes.

The Takeovers Panel has directed Emu NL and its former directors to cover a combined $41,712 in costs incurred by Wayburn Holdings during takeover proceedings, underscoring ongoing regulatory scrutiny.

APC Minerals Limited has initiated a fully underwritten pro-rata renounceable entitlement offer to raise approximately $1.38 million at $0.004 per share, aiming to fund its exploration projects and working capital needs.

A former director of Emu NL has lodged a formal application with the Takeovers Panel, contesting the legitimacy of a recent $1.4 million institutional placement and alleging undisclosed attempts to influence board control.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition, ordering Cosette Pharmaceuticals to comply with conditions preventing closure of the Salisbury manufacturing site. This ruling highlights concerns over market transparency and the integrity of the takeover process.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition after Cosette Pharmaceuticals changed its intentions to close the Salisbury manufacturing site, raising concerns over market transparency and regulatory approval.

The Takeovers Panel has intervened in the Mayne Pharma and Cosette Pharmaceuticals scheme, issuing interim orders that extend the deal deadline and restrict termination rights to maintain the status quo.

The Takeovers Panel has issued interim orders extending the deadline for Mayne Pharma's takeover scheme with Cosette Pharmaceuticals, preventing termination without consent and maintaining the status quo.

An application to the Takeovers Panel questions the integrity of Maronan Metals’ recent $16 million placement and its share purchase plan, raising concerns about undisclosed relationships and share price manipulation.